icad inc. (ICAD) Shares Sold by Bank of New York Mellon Corp
Bank of New York Mellon Corp reduced its position in shares of icad inc. (NASDAQ:ICAD) by 0.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 28,912 shares of the technology company’s stock after selling 247 shares during the period. Bank of New York Mellon Corp owned approximately 0.18% of icad inc. worth $121,000 at the end of the most recent quarter.
Separately, Essex Investment Management Co. LLC grew its holdings in icad inc. by 822.3% during the second quarter. Essex Investment Management Co. LLC now owns 139,766 shares of the technology company’s stock worth $586,000 after acquiring an additional 124,612 shares during the period. 23.14% of the stock is owned by institutional investors.
In related news, Director Dr Lawrence Howard purchased 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 23rd. The stock was acquired at an average price of $3.33 per share, for a total transaction of $33,300.00. Following the transaction, the director now directly owns 488,022 shares of the company’s stock, valued at approximately $1,625,113.26. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 19.20% of the company’s stock.
A number of research analysts recently issued reports on ICAD shares. Laidlaw reaffirmed a “buy” rating and set a $11.00 target price on shares of icad inc. in a report on Tuesday, July 25th. ValuEngine lowered icad inc. from a “sell” rating to a “strong sell” rating in a report on Thursday, September 7th.
icad inc. (ICAD) opened at $4.45 on Tuesday. icad inc. has a fifty-two week low of $2.82 and a fifty-two week high of $6.07.
icad inc. (NASDAQ:ICAD) last released its quarterly earnings results on Tuesday, August 8th. The technology company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.03. icad inc. had a negative return on equity of 44.39% and a negative net margin of 34.74%. The business had revenue of $6.41 million during the quarter, compared to analyst estimates of $6.41 million. analysts anticipate that icad inc. will post -0.51 EPS for the current year.
icad inc. Company Profile
iCAD, Inc is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy).
Receive News & Ratings for icad inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for icad inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.